tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

HUTCHMED and Innovent’s New Drug Application for Renal Cancer Therapy Accepted in China
Company AnnouncementsHUTCHMED and Innovent’s New Drug Application for Renal Cancer Therapy Accepted in China
5d ago
Hutchmed, Innovent jointly announce NDA acceptance in China
PremiumThe Fly
Hutchmed, Innovent jointly announce NDA acceptance in China
5d ago
HCM
HUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer Treatment
PremiumCompany Announcements
HUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer Treatment
8d ago
HUTCHMED Announces Total Voting Rights and Share Capital Update
PremiumCompany Announcements
HUTCHMED Announces Total Voting Rights and Share Capital Update
11d ago
HUTCHMED to Present Promising Oncology Data at 2025 ASCO Meeting
PremiumCompany Announcements
HUTCHMED to Present Promising Oncology Data at 2025 ASCO Meeting
18d ago
Hutchmed downgraded to Hold from Buy at HSBC
PremiumThe FlyHutchmed downgraded to Hold from Buy at HSBC
27d ago
HCM
HUTCHMED Successfully Passes All Resolutions at 2025 AGM
Premium
Company Announcements
HUTCHMED Successfully Passes All Resolutions at 2025 AGM
28d ago
HUTCHMED to Showcase New Data at AACR 2025, Enhancing Oncology Portfolio
Premium
Company Announcements
HUTCHMED to Showcase New Data at AACR 2025, Enhancing Oncology Portfolio
2M ago
HUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric Cancer
PremiumCompany Announcements
HUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric Cancer
2M ago
HUTCHMED Releases 2024 Annual Report and Announces Hybrid AGM
PremiumCompany Announcements
HUTCHMED Releases 2024 Annual Report and Announces Hybrid AGM
2M ago
HUTCHMED Announces Approval of Key Resolution at Extraordinary General Meeting
PremiumCompany Announcements
HUTCHMED Announces Approval of Key Resolution at Extraordinary General Meeting
2M ago
Hutchmed says NDA for Tazverik granted conditional approval in China
PremiumThe Fly
Hutchmed says NDA for Tazverik granted conditional approval in China
3M ago
HCM
HUTCHMED Secures NMPA Approval for TAZVERIK® in China
PremiumCompany AnnouncementsHUTCHMED Secures NMPA Approval for TAZVERIK® in China
3M ago
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
Premium
Ratings
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
3M ago
HCM
HUTCHMED Announces Board Changes Following Director Retirements
Premium
Company Announcements
HUTCHMED Announces Board Changes Following Director Retirements
3M ago
HUTCHMED’s Savolitinib Shows Promising Results in Lung Cancer Trials
PremiumCompany Announcements
HUTCHMED’s Savolitinib Shows Promising Results in Lung Cancer Trials
3M ago
HUTCHMED Files Annual Report with SEC, Affirming Market Position
PremiumCompany Announcements
HUTCHMED Files Annual Report with SEC, Affirming Market Position
3M ago
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
PremiumThe Fly
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
3M ago
HCM
Hutchmed reports FY24 EPS 22c vs. 59c last year
PremiumThe Fly
Hutchmed reports FY24 EPS 22c vs. 59c last year
3M ago
HCM
HUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments
PremiumCompany AnnouncementsHUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments
3M ago
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
Premium
The Fly
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
3M ago
HCM
HUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma
Premium
Company Announcements
HUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >